CTOs on the Move

CEL-SCI

www.cel-sci.com

 
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body`s natural defense system.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.cel-sci.com
  • 8229 Boone Boulevard Suite 802
    Vienna, VA USA 22182
  • Phone: 703.506.9460

Executives

Name Title Contact Details

Funding

CEL-SCI raised $10M on 06/30/2020
CEL-SCI raised $31.7M on 06/11/2021

Similar Companies

One Tast

One Tast is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Azitra

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease.

Landmark Bio

Formerly known as the new center for advanced biological innovation and manufacturing (or “CABIM”), Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today`s cutting-edge research into tomorrow`s breakthrough therapies. The cross-sector partnership harnesses world-leading expertise to accelerate fast-emerging and promising science, the challenges of which are daunting for any single institution to tackle alone. Board members include leaders from Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children`s Hospital, Brigham and Women`s Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Massachusetts Life Sciences Center.

Greffex

Greffex™ is a privately held, multi-national company, headquartered in Aurora, Colorado. Established in 1999, Greffex has developed a novel genetic platform for the development and production of vaccines. Our proprietary GREVAX™ Universal Platform delivers vaccines in a faster, more affordable and more efficient manner. Once a pathogen has been identified, Greffex`s team designs and produces a GREVAX™ vaccine in as little as 4 weeks. The state-of-the-art flexibility of the GREVAX™ Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, Anthrax and Dengue Fever, as well as Malaria, Hepatitis C, Respiratory Syncytial Virus (RSV), Ebola, HPV, Plague, Tuberculosis and a host of other vaccine candidates.

Royal Danish Consulate

Royal Danish Consulate is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.